Stifel analyst Alex Thompson CFA maintains $RAPT Therapeutics (RAPT.US)$ with a hold rating, and maintains the target price at $2.
According to TipRanks data, the analyst has a success rate of 61.2% and a total average return of 17.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $RAPT Therapeutics (RAPT.US)$'s main analysts recently are as follows:
Rapt Therapeutics' recent discontinuation of the zelnecirnon program came after FDA feedback indicated challenges in disproving drug-induced liver failure. The lack of data disclosure and the uncertainty that surrounds the development of next-generation compounds, which may require additional capital, suggests Rapt now needs to demonstrate more to gain confidence.
The FDA's request for definitive evidence concerning liver SAEs was more conservative than expert expectations. Despite this, there is an observed efficacy signal from Phase 2b, which is promising for the next-generation compound. Further data is anticipated to evaluate the potential.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
斯迪富分析師Alex Thompson CFA維持$RAPT Therapeutics (RAPT.US)$持有評級，維持目標價2美元。
根據TipRanks數據顯示，該分析師近一年總勝率為61.2%，總平均回報率為17.5%。
此外，綜合報道，$RAPT Therapeutics (RAPT.US)$近期主要分析師觀點如下：
Rapt therapeutics最近停止zelnecirnon項目，原因是在FDA的反饋中指出在反駁藥物引起的肝功能衰竭方面存在挑戰。缺乏數據披露以及圍繞下一代compound的開發存在的不確定性，可能需要額外的資金，這表明Rapt現在需要展示更多以獲得信任。
FDA對肝臟嚴重不良事件的明確證據的請求比專家預期更爲保守。儘管如此，20億階段觀察到了有效信號，這對下一代compound來說是令人鼓舞的。預計將有進一步的數據評估該潛力。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
